A Phase 3, Multicentre, Randomized, Double-blind, Placebo-controlled Study Investigating the Efficacy and Safety of Daily Oral Administration of OBE2109 Alone and in Combination With Add-back Therapy for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women

Trial Profile

A Phase 3, Multicentre, Randomized, Double-blind, Placebo-controlled Study Investigating the Efficacy and Safety of Daily Oral Administration of OBE2109 Alone and in Combination With Add-back Therapy for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women

Recruiting
Phase of Trial: Phase III

Latest Information Update: 26 Jul 2017

At a glance

  • Drugs KLH 2109 (Primary)
  • Indications Uterine leiomyoma
  • Focus Therapeutic Use
  • Acronyms PRIMROSE 1
  • Sponsors ObsEva
  • Most Recent Events

    • 25 Apr 2017 According to an ObsEva media release, the first clinical centers are opened and started the recruitment of patients.
    • 25 Apr 2017 Status changed from not yet recruiting to recruiting, according to an ObsEva media release.
    • 09 Mar 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top